An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · NXP Semiconductors N.V.
VERDICT
The label
Distribution
read at $267.67
NXP Semiconductors holds its Distribution at $267.67.
PHPhase · the trend structure carries the Distribution label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-27
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 18 days
Price
$267.67
Valuation
254.92 trailing · 14.95 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.81
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades above our $232.13 fair value estimate, strong competitive moat, 12.20% revenue growth.
Read at
$267.67
254.92 P/E · 14.95 fwd
Our fair value
$232.13
13% premium
Analyst target (avg)
$313.00
+17% to current
Target low $200.00Analyst target rangeTarget high $400.00
▲ current $267.67 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$267.67
you are here
Conservative
$180.00
-33%
Analyst avg
$313.00
+17%
Our fair value
$232.13
-13%
Analyst high
$400.00
+49%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Revenue growth
12.20%
Profit margin
21.03%
Debt to equity
103.99
Analyst consensus
Buy · 29 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is 46.0% of its assets, above the one-third ceiling the screen allows. Against market value it is 17.4%, under the 30% line the market-value standard uses — so that standard clears it.Divergent
Interest-bearing cashCash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 14.9% of assets, under the 49% limit.Pass
Revenue purityOnly 1.2% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Chipmaker looks cheap but hides cyclical traps
Every phone, car and factory machine needs chips, yet NXP trades at a forward multiple of 14.9 times earnings with revenue growth of 12 percent and a 21 percent profit margin. The business carries a strong moat and 26 percent ROE, yet our fair value sits 14 percent below the current price of 266 dollars, so we pass. The ethical screen also flags excessive debt, ruling the name out regardless of analyst targets near 310 dollars.
This is a classic cyclical value trap. Peak cycle earnings often flatter the multiple and mask the sharp drops that follow when auto and industrial demand turns. Strong returns on equity can vanish quickly once volumes fall, leaving investors holding inventory and capacity that suddenly looks expensive.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Netherlands and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
NXPI trades on a US exchange (the company is based in Netherlands). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis. Entered 2026-07-27 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-27Markup$266.53+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Markup$266.53+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Markup$266.53+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Markup$266.53+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Markup$266.53+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-22Markup$266.53+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21Markup$266.53+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Markup$266.53-9.9%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markup$295.96+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (31 analysts) rates it buy, with a mean price target of $302.
2026-07-03Markup$295.96+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.